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SUMMARY
What is known and objective: Tuberculosis is still a major
infectious disease in Indonesia. Patients are treated mostly using
ﬁxed-dose combination treatment in primary public health
facilities. The incidence of antituberculosis drug-induced liver
injury (AT-DILI) is approximately 10% among Indonesian
tuberculosis patients who used standard ﬁxed combination
regimens during the intensive phase of treatment. However,
information regarding genetic polymorphism associated with
the increase risk of drug-induced liver injury is still limited. The
aim of this study was to investigate pregnane X receptor (PXR)
gene polymorphisms as one of the risk factors of AT-DILI.
Methods: In this prospective cohort study, we recruited 106 adult
patients diagnosed with pulmonary tuberculosis and treated
with category I FDC (ﬁxed-dose combination). The identiﬁcation
of SNP -25385C>T (rs3814055) was conducted by ARMS (ampli-
ﬁcation refractory mutation system). Hepatotoxicity was deﬁned
as ALT and/or AST levels above the normal threshold on the
second, fourth and sixth months of monitoring during tubercu-
losis treatment.
Results and discussion: The logistic regression analysis showed
that patients with the TT genotype of PXR gene (rs3814055)
signiﬁcantly had a greater risk of AT-DILI (OR 889; 95% CI
136–5793, P < 005), compared with those of wild-type CC
genotype.
What is new and conclusion: The result suggests that in
Indonesian patients with tuberculosis, the risk of having AT-
DILI was associated with TT genotype of the PXR gene.
WHAT IS KNOWN AND OBJECTIVE
Tuberculosis (TB) is an infectious disease that is still a major
problem in developing countries, including Indonesia. In 2014, the
World Health Organization categorized Indonesia as a high-TB-,
multi-drug resistant (MDR)-TB-, and human immunodeﬁciency
virus (HIV)-burdened country. There are an estimated 90 million
incident cases of TB and 15 million people died of the disease each
year (11 million deaths were HIV negative, and 360 000 were HIV
positive). The corresponding ﬁgures for Indonesia are 325 582, and
7964 cases of TB have been identiﬁed as new and relapse cases,
respectively.1 Given this high burden of disease, the government of
Indonesia is focusing on the control and elimination of TB. One of
the efforts is through the directly observed treatment, short-course
strategy (DOTS) programme.
One of the main concerns in antituberculosis drugs (ATDs) is
drug-induced liver injury (DILI) or hepatotoxicity caused by
drugs.2 Of the ﬁrst-line anti-TB drugs, isoniazid, pyrazinamide
and rifampicin can all cause liver damage (drug-induced hepati-
tis).3 In addition, rifampicin can cause asymptomatic jaundice
without evidence of hepatitis.3 A previous publication has shown
that the incidence of antituberculosis drug-induced liver injury
(AT-DILI) is around 10% among Indonesian TB patients treated
with standard ﬁxed combination regimens during the intensive
phase of treatment.4 Many researchers have reported on speciﬁc
gene polymorphisms as risk factors for those hepatotoxic effects.
Some of the reported genes are N-acetyltransferase 2 (NAT2),5–10
cytochrome P450 2E1 (CYP2E1),9,11,12 glutathione S-transferase
mu-1 (GSTM1)9,10,13 and glutathione S-transferase theta (GSTT).9,13
Other genes also reported to be potential predictors of ATDs-DILI
are pregnane X receptor (PXR), glutathione S-transferase alpha-1
(GSTA1), manganese superoxide dismutase (MnSOD, SOD2),
UDP-glucuronosyltransferase (UGT), nitric oxide synthase 2A
(NOS2A), BTB and CNC homology 1 (BACH1), Maf basic leucine
zipper protein (MAFK), and human leucocyte antigen (HLA).14–18
We examined PXR gene polymorphism because ligand forma-
tion between rifampicin and PXR could trigger the expression
of various genes, including various cytochromes and car-
boxylesterases that may be relevant to the metabolism of isoniazid
in producing hepatotoxic metabolites. PXR plays a role in the
regulation of a number of hepatic and intestine genes involved in
detoxiﬁcation and elimination of xenobiotics.19 The polymor-
phisms are generally located in the 50-ﬂanking region of the target
genes.20 PXR activates various genes through binding and
heterodimer formation with the retinoid X receptor (RXR). PXR
ligands stimulates the expression of genes involved in xenobiotics
oxidation (phase I), conjugation (phase II) and transport (phase III)
in the liver. PXR is involved in phase I metabolism through
the expression of CYP2B6, CYP2C8, CYP2C9, CYP2B9 and
CYP2C19.21–25 Moreover, PXR is involved in phase II metabolism
through the expression of glutathione S-transferase (GST),
sulfotransferase, UDP-glucuronosyltransferase and carboxyles-
terase.26–31 PXR is involved in phase III through the expression of
organic anion transporting polypeptide 2(OATP2) and multiple
drug resistance protein 2 (MRP2).32–34 This study aimed to
investigate possible associations of PXR gene polymorphisms with
the increased risk of ATDs-DILI.
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METHODS
Patients
A total of 106 patients with active lung TB who visited selected
primary public health facilities in Bandar Lampung and Yogya-
karta were enrolled consecutively and followed up in this
prospective cohort study. Inclusion criteria were as follows: (i)
adult patients (over 18 years of age) newly diagnosed with active
lung TB, (ii) treated with ﬁxed-dose combination of antitubercu-
losis drugs (FDC-ATD) category I using directly observed treat-
ment, short-course strategy (DOTS) and (iii) have agreed to the
terms in the written informed consent. Patients with any of the
following conditions were excluded from the study: (i) positive
HIV/AIDS, (ii) abnormal serum ALT and AST levels over twice
upper limit of normal (ULN) value before treatment with ATD, (iii)
with hepatitis or have a history of hepatitis, (iv) haemoglobin
serum <8 mg/dL, (v) not having ATDs for over 2 weeks, (vi) have
a history of kidney disease and (vii) refusal to blood collection.
All patients received FDC-ATD category I intensive phase
(rifampicin 150 mg, isoniazid 75 mg, pyrazinamide 400 mg and
ethambutol 275 mg per tablet) and FDC-ATD category I contin-
uation phase (rifampicin 150 mg and isoniazid 150 mg) in
6 months of therapy. The dosage of ATDs was selected according
to the patients’ weight. ALT and AST serum levels were obtained
ﬁve times: before ATD treatment, after completing the second, the
fourth, the sixth months of ATD therapy and 1 month after the
patient ﬁnished the last ATDs therapy. Antituberculosis drug-
induced liver disease (ATD-DILI) was designated as an increase in
serum ALT and AST levels above the ULN after ATDs treatment,
according to the criteria of drug-induced liver injuries developed
by Drug-Induced Liver Injury Network (DILIN), National Institute
of Diabetes and Digestive and Kidney Diseases (NIDDK), and
Division of Specialized Information Services of the National
Library of Medicine (NLM), and National Institutes of Health
and Common Toxicity Criteria for Adverse Events 4.0 version
(CTCAE v.4.0, Bethesda, MD, USA).35
The written informed consent was obtained from each patient
enrolled in this study. This study protocol conformed to the ethical
guidelines of the 1975 Declaration of Helsinki and was approved
by the Ethics Committee for Health Research, National Institute of
Health Research and Development, Ministry of Health, Republic of
Indonesia.
Single Nucleotide Polymorphism genotyping
DNA was extracted from the peripheral blood sample collected
from each patient using the standard proteinase K digestion and
GeneJET Genomic DNA Puriﬁcation Kit (Thermo Scientiﬁc,
Walthman, MA, USA.). Polymerase chain reaction–ampliﬁcation
refractory mutation system (PCR-ARMS) was used to detect the -
25385C>T (rs3814055) PXR polymorphisms located in the 50UTR
promoter. The two primer sets were as follows: forward 50-
TTTTGGCAATCCCAGGTTT-30 to detect PXR polymorphic gene
(F-primer – 1) and 50-TTTTGGCAATCCCAGGTTC-30 to conﬁrm
normal fragment gene (F-primer – 2); reverse 50-CGAATGTGGTG-
GATACCAG-30. PCR was carried out using 5x FIREPol Master
Mix Ready from Solis BioDyne (Tartu, Estonia), according to the
manufacturer’s instruction. Initial denaturation at 95 °C for 4 min
was followed by 40 cycles of denaturation at 95 °C for 30 s,
annealing at 597 °C, extension at 72 °C for 1 min, with ﬁnal
extension at 72 °C for 7 min. The products obtained were
electrophoresed on 2% agarose gels. Polymorphic gene TT showed
219-bp PCR product only when it was identiﬁed using F-1 forward
primer, non-polymorphic gene CC showed 219 bp only when it
was identiﬁed using F-2 reverse primer, and heterozygote gene CT
showed 219 bp when it was identiﬁed using both forward
primers.
Statistical analysis
Allele frequencies were calculated, and the agreement between the
allele frequencies and Hardy–Weinberg equilibrium was tested
using a chi-square test (d.f. = 1) for each locus. Odds ratios (ORs)
and 95% conﬁdence intervals (95% CIs) were calculated using
binomial logistic regression analysis, adjusting for sex and age. The
baseline ALT and AST differences among genotype groups were
determined using the Kruskal–Wallis test. Statistical analyses were
performed using a data analysis freeware.
RESULTS AND DISCUSSION
Results
The result of UV gel visualization is shown in Fig. 1. Homozygotes
TT and CC showed single bands on F-primer 1 and F-primer 2,
respectively. Heterozygote CT showed double bands with the F-
primer 1 and F-primer 2.
Seven patients (66%) were TT homozygotes, 32 patients
(3019%) were CT heterozygotes, and most patients (67; 6321%)
were wild-type CC homozygotes. The genotype frequencies were
not different from those predicted by the Hardy–Weinberg
equation (Table 1).
Table 2 shows that there was no statistical difference in ALT
and AST baseline levels among both male and female patients with
different genotypes (P > 005). The mean of ALT and AST levels
increased at the end of the ﬁrst 2 months of ATD therapy or after
completion of the intensive phase and decreased during the
continuous phase (Table 3). Most of the patients (71 patients;
6698%) experienced no hepatotoxicity, but 35 patients showed
elevated transaminase levels. The transaminase elevation was seen
in 33 patients (3113%) with mild hepatotoxicity (1+) and 2 patients
(189%) with moderate hepatotoxicity (2+) (Table 4).
219 bp
Sample 1 (TT) Sample 2 (CC) Sample 3 (CT)
Fig. 1. UV visualization result of 25385C>T (rs3814055) polymor-
phisms.
Table 1. Comparison of observed and expected genotype
frequency based on Hardy–Weinberg equilibrium
Genotypes Observed Expected P value
CC 67 65 025
CT 32 36
TT 7 5
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The risk of having ATD-DILI was signiﬁcantly associated with
the TT genotype. For this genotype, the risk of having an ATD-
DILI was 889-fold (OR: 889; 95% CI: 136–5793; P = 0022) that of
the wild-type (CC genotype) (Table 5). The results also show that
the combined (CT + TT) genotype had a tendency for higher
incidence of ATD-DILI in comparison with the wild-type CC
genotype (OR: 132; 95% CI: 056–314; P = 0525). We also found
that the risk of an ATD-DILI in females was 264-fold (OR: 264;
95% CI: 106–657; P = 0036) that of males.
Discussion
We found that there was a signiﬁcant association between the
variant TT homozygote of PXR (-25385C>T; rs3814055) and the
risk of AT-DILI. This result is consistent with results reported by
Andrews et al.36 who reported that a different PXR polymorphism
at the same location was signiﬁcantly associated with liver injury
caused by ﬂucloxacillin, a PXR agonist. Andrews et al. concluded
that the CC genotype was associated with the risk of ﬂucloxacillin-
induced liver injury. However, a previous study conducted in
Europe and South Asia reported no association between ATDs and
PXR gene polymorphism in patients.37
As genetic polymorphism is only one of the many factors that
may contribute to drug-induced hepatotoxicity, its signiﬁcance
requires further testing.38 Rifampicin is a PXR agonist. PXR is
involved in the regulation of bile acid and cholesterol homeostasis.




n (%) Mean  SD n (%) Mean  SD n (%) Mean  SD
Sex
Male 5 (7143) 18 (5625) 49 (7313)
Female 2 (2857) 14 (4375) 18 (2687)
Total 7 (10000) 32 (10000) 67 (10000)
Age group (years)
18–45 4 (5714) 23 (7188) 46 (6866)
46–55 1 (1429) 6 (1875) 13 (1940)
>55 2 (2857) 3 (938) 8 (1194)
Total 7 (10000) 32 (10000) 67 (10000)
ALT baseline
Male 3120  855 2456  287 2122  196 0195
Female 1200  200 1707  313 1494  138 0767
AST baseline
Male 3360  870 2600  300 2149  135 0053
Female 1750  250 2121  263 2067  140 0754
Table 3. Serum aminotransferase level cohort data according to
sex
Min (g/dL) Max (g/dL) Mean  SE (g/dL)
Male
ALT
Baseline 500 9100 2275  163
2nd month 900 21800 2543  318
4th month 500 4600 1800  097
6th month 500 7700 1931  148
8th month 700 7600 2096  139
AST
Baseline 800 7000 2346  136
2nd month 1000 16700 2776  227
4th month 1100 4600 2381  087
6th month 900 6300 2412  103
8th month 900 5100 2293  088
Female
ALT
Baseline 800 5500 1565  147
2nd month 800 4900 1891  179
4th month 500 5900 1735  219
6th month 600 7400 1974  305
8th month 500 6400 2074  224
AST
Baseline 1100 5200 2071  130
2nd month 1000 4900 2291  149
4th month 1000 5300 2318  163
6th month 800 6700 2347  213
8th month 1300 4400 2312  119
Table 4. Frequency of hepatotoxicity according to severity of
drug-induced hepatotoxicity
Drug-induced Hepatotoxicity Level n (%)
1+, Mild (<25 9 ULN) 33 (3113)
2+, Moderate (25–5 9 ULN) 2 (189)
No hepatotoxicity 71 (6698)
Total 106 (10000)
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Some of the bile acids are toxic. Therefore, the regulation by PXR of
the expression of proteins involved in both phase I and phase II
drug metabolism and transport requires further investigation.39
Murine studies with the humanized pregnane X receptor (hPXR)
suggested that rifampicin and isoniazid combination therapy leads
to accumulation of protoporphyrin IX, an endogenous hepatotoxin
through a mechanism involving PXR’s effect on the haem
biosynthesis pathway.40
This study also indicates that females are signiﬁcantly more
likely to show ATD-DILI than males. This is consistent with some
previous studies which showed that female patients were
more likely to show hepatotoxicity.41–43 They also reportedly
show a higher risk of hepatotoxicity with nitrofurantoin,
erythromycin, ﬂucloxacillin, minocycline and isoniazid.44
Drug-induced hepatotoxicity in females tends to be hepatocellular
with vascular damage on the centrilobular vein.44,45 The presence
of genetic abnormality in the mitochondria is also said to be a
major determinant of idiosyncratic drug-induced hepatotoxicity
especially in women and the elderly.46
Our study has some limitations because we did not use other
liver function parameters such as total serum bilirubin, serum
ALP, INR and GGT. Their measurements would have been useful
in deﬁning liver function and the severity of hepatotoxicity better.
We were also not able to assess other confounding factors, such as
exposure to hepatotoxic agents including commonly encountered
items such as acetaminophen, potentially hepatotoxic herbal and
food products, and other chemicals in the patient’s environment.
The small number of PXR T homozygotes calls for a larger
conﬁrmatory study.
WHAT IS NEW AND CONCLUSION
We found a signiﬁcant association between the PXR TT variant
(-25385C>T; rs3814055) and the AT-DILI. Whether testing for PXR
genotype will provide reliable predictions of AT-DILI requires
further validation.
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